<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646566</url>
  </required_header>
  <id_info>
    <org_study_id>DP10019</org_study_id>
    <nct_id>NCT02646566</nct_id>
  </id_info>
  <brief_title>Study of APD421 as PONV Treatment (Prior Prophylaxis)</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless,
      dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established
      PONV, in patients who have had prior PONV prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response (Success of Initial PONV Treatment)</measure>
    <time_frame>0-24 hours after administration of study medication</time_frame>
    <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response 0-2 Hrs</measure>
    <time_frame>0-2 hours after administration of study medication</time_frame>
    <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response 0-4 Hrs</measure>
    <time_frame>0-4 hours after administration of study medication</time_frame>
    <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 4 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 4-hour period after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response 0-6 Hrs</measure>
    <time_frame>0-6 hours after administration of study medication</time_frame>
    <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 6 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 6-hour period after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>0-24 hours after study drug administration</time_frame>
    <description>Time to first violation of the criteria for complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incidence of Emesis</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Receiving Rescue Medication</measure>
    <time_frame>0-24 hours after study drug administration</time_frame>
    <description>Number of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With an Incidence of Significant Nausea</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Number of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With an Incidence of Nausea</measure>
    <time_frame>30 mins to 24 hours after drug administration</time_frame>
    <description>Number of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Severity of Nausea</measure>
    <time_frame>30 mins to 24 hours after study drug administration</time_frame>
    <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution Score of Nausea (0-180 Mins)</measure>
    <time_frame>0-180 minutes after study drug administration</time_frame>
    <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at five pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes and 2 hours after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">705</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>APD421 standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (standard) dose IV APD421</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD421 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (high) dose IV APD421</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <arm_group_label>APD421 high</arm_group_label>
    <arm_group_label>APD421 standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients ≥ 18 years of age

          -  Provision of written informed consent

          -  Patients scheduled to undergo elective surgery (open or laparoscopic technique) under
             general anaesthesia (other than total intravenous anaesthesia with propofol) expected
             to last at least one hour from induction of anaesthesia to extubation

          -  Patients judged by the investigator to have a moderate or high risk of experiencing
             PONV. In forming this judgment, investigators should pay particular attention to risk
             factors such as a past history of PONV and/or motion sickness; habitual non-smoking
             status; female sex; and likely use of opioid analgesia post-operatively.

          -  For females of child-bearing potential: ability and willingness to use a highly
             effective form of contraception (as defined in ICH M3 guidance, e.g., abstinence from
             sexual intercourse, surgical sterilisation (of subject or partner), combined oral
             contraceptive pill, a double-barrier method of contraception such as either an
             intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with
             partner's use of a condom, or any other method or combination of methods with a
             failure rate generally considered to be &lt;1% per year) between the date of screening
             and at least 48 hours after administration of study drug

          -  In order to be eligible for randomisation, subjects must also:

             (i) have experienced a first episode of PONV not more than 24 hours after the end of
             their operation (wound closure) and prior to discharge from hospital (&quot;qualifying PONV
             episode&quot;), for which they have not already received any anti-emetic treatment; and
             (ii) not have received any dopamine-antagonist agent likely to prevent or treat nausea
             or vomiting (given as prophylaxis or otherwise) in the period from 24 hours prior to
             the start of their operation up to the time of the qualifying PONV episode.

        Exclusion Criteria:

          -  Patients scheduled to undergo transplant surgery or any surgery where post-operative
             emesis may pose a significant danger to the patient

          -  Patients planned to receive only a local anaesthetic and/or regional neuraxial
             (intrathecal or epidural) block

          -  Patients who have received APD421 active ingredient for any indication within the last
             2 weeks

          -  Patients who are allergic to APD421 active ingredient or any of the excipients of
             APD421

          -  Patients with a significant, ongoing history of vestibular disease or dizziness

          -  Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or
             breast cancer) or phaeochromocytoma.

          -  Patients with documented or suspected alcohol or substance abuse within the past 6
             months.

          -  Patients with direct or indirect evidence of clinically significant hypokalaemia, such
             as a serum potassium level &lt; 3.0 mmol/L.

          -  Patients who have received in the post-operative period, and prior to receiving study
             drug, any medication with a substantial risk of inducing torsades de pointes,
             including Class Ia antiarrhythmic agents such as quinidine, disopyramide,
             procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and
             other medications such as bepridil, cisapride, thioridazine, methadone, IV
             erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin, etc.

          -  Patients who have a documented, clinically significant cardiac arrhythmia or
             congenital long QT syndrome.

          -  Patients who are pregnant or breast feeding.

          -  Patients being treated with levodopa.

          -  Patients diagnosed with Parkinson's disease.

          -  Patients who have received emetogenic anti-cancer chemotherapy in the previous 4
             weeks.

          -  Patients with a history of epilepsy.

          -  Any other concurrent disease or illness that, in the opinion of the investigator makes
             the patient unsuitable for the study.

          -  Patients who have previously participated in this study or who have participated in
             another interventional clinical study involving pharmacological therapy within the
             previous 28 days (or longer exclusion period, if required by national or local
             regulations).

          -  Where local laws/regulations require: patients under legal protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Fox, MB BChir</last_name>
    <role>Study Director</role>
    <affiliation>Acacia Pharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Aue</name>
      <address>
        <city>Aue</city>
        <zip>08280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps University</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>November 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2018</results_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Estimated recruitment was 700, to deliver 690 evaluable, randomised patients, providing an average of 230 evaluable patients in each of the three groups. The number of randomised patients planned per country was as follows: Germany, 190; France, 15; Canada, 100; and USA, 395</recruitment_details>
      <pre_assignment_details>Three patients were randomised but not dosed: 2 due to withdrawal of consent, 1 for other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>APD421 5mg</title>
          <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="P2">
          <title>APD421 10mg</title>
          <description>APD421 10mg administered as a single,slow intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching Placebo administered as a single, slow intravenous (IV) push over about two minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="230"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>APD421 5mg</title>
          <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="B2">
          <title>APD421 10mg</title>
          <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="237"/>
            <count group_id="B2" value="230"/>
            <count group_id="B3" value="235"/>
            <count group_id="B4" value="702"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="634"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="13.12"/>
                    <measurement group_id="B2" value="46.9" spread="13.03"/>
                    <measurement group_id="B3" value="46.0" spread="13.38"/>
                    <measurement group_id="B4" value="46.3" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="633"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="578"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response (Success of Initial PONV Treatment)</title>
        <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
        <time_frame>0-24 hours after administration of study medication</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response (Success of Initial PONV Treatment)</title>
          <description>The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was a comparison of the incidence of the primary efficacy variable between the two groups that received APD421 and the group that received placebo, using Pearson’s χ2 test. The threshold for determining statistical significance in the comparison of incidence of success between the active and placebo groups (the primary efficacy analysis) was a p-value of 2.5% one-sided.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>One-sided p-value. After adjustment for multiplicity using Hommel's method. (Note: unadjusted p value = 0.003) A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was a comparison of the incidence of the primary efficacy variable between the two groups that received APD421 and the group that received placebo, using Pearson’s χ2 test. The threshold for determining statistical significance in the comparison of incidence of success between the active and placebo groups (the primary efficacy analysis) was a p-value of 2.5% one-sided.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <p_value_desc>One-sided p-value. After adjustment for multiplicity using Hommel's method. (Note: unadjusted p value = 0.109) A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response 0-2 Hrs</title>
        <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
        <time_frame>0-2 hours after administration of study medication</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response 0-2 Hrs</title>
          <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response 0-4 Hrs</title>
        <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 4 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 4-hour period after administration of study medication.</description>
        <time_frame>0-4 hours after administration of study medication</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response 0-4 Hrs</title>
          <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 4 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 4-hour period after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response 0-6 Hrs</title>
        <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 6 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 6-hour period after administration of study medication.</description>
        <time_frame>0-6 hours after administration of study medication</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response 0-6 Hrs</title>
          <description>Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 6 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 6-hour period after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>One-sided p-value. No adjustment for multiple comparisons. A priori threshold for statistical significance = 0.025.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to first violation of the criteria for complete response</description>
        <time_frame>0-24 hours after study drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to first violation of the criteria for complete response</description>
          <population>Modified ITT population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="43" upper_limit="NA">Treatment failure occurred in less than 75% of patients</measurement>
                    <measurement group_id="O2" value="443" lower_limit="70" upper_limit="NA">Treatment failure occurred in less than 75% of patients</measurement>
                    <measurement group_id="O3" value="120" lower_limit="35" upper_limit="NA">Treatment failure occurred in less than 75% of patients</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incidence of Emesis</title>
        <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incidence of Emesis</title>
          <description>Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Receiving Rescue Medication</title>
        <description>Number of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
        <time_frame>0-24 hours after study drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Receiving Rescue Medication</title>
          <description>Number of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With an Incidence of Significant Nausea</title>
        <description>Number of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Incidence of Significant Nausea</title>
          <description>Number of patients with nausea score ≥4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.315</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With an Incidence of Nausea</title>
        <description>Number of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Incidence of Nausea</title>
          <description>Number of patients with nausea score ≥1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.520</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Severity of Nausea</title>
        <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
        <time_frame>30 mins to 24 hours after study drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Severity of Nausea</title>
          <description>Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.</description>
          <population>Modified ITT population</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.08"/>
                    <measurement group_id="O2" value="3.6" spread="3.03"/>
                    <measurement group_id="O3" value="4.2" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.420</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution Score of Nausea (0-180 Mins)</title>
        <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at five pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes and 2 hours after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
        <time_frame>0-180 minutes after study drug administration</time_frame>
        <population>Modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg</title>
            <description>APD421 5mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O2">
            <title>APD421 10mg</title>
            <description>APD421 10mg administered as a single, slow intravenous (IV) push over about two minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered as a single, slow, IV push over about two minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Evolution Score of Nausea (0-180 Mins)</title>
          <description>The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at five pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes and 2 hours after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.</description>
          <population>Modified ITT population</population>
          <units>Score on a scale*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6994.7" spread="5659.6"/>
                    <measurement group_id="O2" value="5637.9" spread="6046.6"/>
                    <measurement group_id="O3" value="7629.2" spread="6640.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.258</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>Any AE that is serious, occurring during the relevant study period (from study drug administration to 7-day follow-up), irrespective of the treatment received by the subject, must be reported to the Pharmacovigilance provider within 24 hours</desc>
      <group_list>
        <group group_id="E1">
          <title>APD421 IV 5mg</title>
          <description>IV dose of APD421 5mg (IV dose)- was administered to each patient in a double-blind fashion, by slow IV push over about two minutes into a peripheral or central venous cannula.</description>
        </group>
        <group group_id="E2">
          <title>APD421 IV 10mg</title>
          <description>IV dose of APD421 10mg (IV dose)- was administered to each patient in a double-blind fashion by slow IV push over about two minutes into a peripheral or central venous cannula.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>IV dose of Placebo (IV dose)- was administered to each patient in a double-blind fashion by slow IV push over about two minutes into a peripheral or central venous cannula.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Fatty tissue prolapse at the tempral lobe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-infectious gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Unspecified Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intra-abdominal Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intractable vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Presacral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomosis Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy bile leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Postoperative rise in creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness in the leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="237"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="230"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="237"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="237"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="237"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats with this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Gabriel Fox</name_or_title>
      <organization>Acacia Pharma</organization>
      <phone>01223875919764</phone>
      <email>GabrielFox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

